Ani Pharmaceuticals (ANIP) Other Accumulated Expenses (2010 - 2013)

Ani Pharmaceuticals has disclosed Other Accumulated Expenses across 4 years of filings, most recently posting $112784.0 for Q1 2013.

• Other Accumulated Expenses for Q1 2013 came in at $112784.0, down 94.46% year-over-year; the trailing twelve-month figure through Mar 2013 was $112784.0 (down 94.46% YoY), and the FY2012 annual result was $502452.0, down 79.74% from the prior year.
• Other Accumulated Expenses came in at $112784.0 for Q1 2013 at Ani Pharmaceuticals, down from $502452.0 in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $2.9 million in Q2 2011 to a low of $112784.0 in Q1 2013.
• The 4-year median for Other Accumulated Expenses is $1.7 million (2010), against an average of $1.6 million.
• Across the five-year window, Other Accumulated Expenses soared 47.43% in 2011 and tumbled 94.46% in 2013, its largest moves.
• Ani Pharmaceuticals' Other Accumulated Expenses stood at $1.7 million in 2010, then surged by 47.43% to $2.5 million in 2011, then plunged by 79.74% to $502452.0 in 2012, then slumped by 77.55% to $112784.0 in 2013.
• The last three Other Accumulated Expenses figures came in at $112784.0 (Q1 2013), $502452.0 (Q4 2012), and $860094.0 (Q3 2012), per Business Quant data.